25C-NB4OMe (2C-C-NB4OMe, NB4OMe-2C-C) is a derivative of the phenethylamine hallucinogen 2C-C, which acts as a partial agonist for the human 5-HT2A receptor.[1]

25C-NB4OMe
Clinical data
ATC code
  • none
Legal status
Legal status
Identifiers
  • 2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(4-methoxyphenyl)methyl]ethanamine
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC18H22ClNO3
Molar mass335.83 g·mol−1
3D model (JSmol)
  • COC1=CC=C(C=C1)CNCCC2=CC(=C(C=C2OC)Cl)OC
  • InChI=1S/C18H22ClNO3/c1-21-15-6-4-13(5-7-15)12-20-9-8-14-10-18(23-3)16(19)11-17(14)22-2/h4-7,10-11,20H,8-9,12H2,1-3H3
  • Key:QEGZBQXBCVUMCU-UHFFFAOYSA-N

Legality

edit

United Kingdom

edit

This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.[2]

References

edit
  1. ^ Hansen M, Phonekeo K, Paine JS, Leth-Petersen S, Begtrup M, Bräuner-Osborne H, Kristensen JL (March 2014). "Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists". ACS Chemical Neuroscience. 5 (3): 243–249. doi:10.1021/cn400216u. PMC 3963123. PMID 24397362.
  2. ^ "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". UK Statutory Instruments 2014 No. 1106. www.legislation.gov.uk.